← Back to Screener

PCVX Report

08-04-2026 | Analyze. Execute. Alpha.

Performance Framework

Earning
Sentiment
Estimate
Short interest
Cdrs
Ta analysis (short term)
Ta analysis (long term)
Insiders action
Institutional conviction
Mf

Key Metrics & Valuation

Market Cap 8.36B$
Next Earning Release 2026-05-06 00:00:00 (NA days)
Correlation to Market -26.4%
Technical Trend Trending up
Current Ratio 7.9
Return on Equity -25.9%
PEG Ratio -0.2
EV/EBITDA -10.8
EV/Revenue 0.0
EV/FCF -12.6
Price to Earning Correlation 16.9%
Total R&D (5yr % of Rev) 0.0%
Institutional Holding 12149.0%

Earnings & Cash Flow

  • This quarter EPS is -61.6% related to same quarter last year.
  • Annual earning is -48.2% compared to last year.
  • EPS (ttm) in the last 4 quarters is trending down .
  • Annual average earning surprise in the last 5 years is 7.9%.
  • Earnings in the last 5 years, is trending down .
  • 4.0 of the last 4 quarters had positive surprise.

EBITDA

  • This quarter EBITDA is -346.2% related to same quarter last year.
  • EBITDA in the last 4 quarters, is trending down.
  • Annual EBITDA in the last 5 years, is trending down.

Free Cash Flow (FCF)

  • This quarter FCF is -15.8% related to same quarter last year.

Revenue/Income

Revenue

  • This quarter revenue is 0.0% related to same quarter last year.

Net Income

  • This quarter income is -79.8% related to same quarter last year.
  • Income ratio in the last 4 quarters, is trending down .
  • Net income ratio in the last 5 years, is trending down .

Sentiment

News Sentiment

  • Short term: 100.0% positive, 0.0% negative.
  • Long term: 100.0% positive, 0.0% negative.

Short Interest

  • Short ratio (Days to cover): 10.6
  • Short as % of float: 10.1%
  • Float share amount is trending down.

Future Estimates

Revenue 0.0%
Net Income -36.1%
EPS -36.1%
Price Target Up Side 48.3%

Company Profile

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Next earning release is on 2026-05-06 00:00:00, in NA days

Technical Analysis

Hourly Momentum

Daily Framework

Weekly Strategic

Interactive Chart

Additional Resources

  • Premium Analysis Locked
  • AI Analyst Reasoning


    Content Locked Premium Analysis Locked (Contact for Access)